**Synthesis of Novel Halogenated Heterocyclic compounds and their uses as Target SARS-CoV-2 main Protease (Mpro) and Potential Anti-Covid-19**

Fahad M. Almutairi,a Rafat M. Mohareb,\*b Abdo A. Elfiky,c Mahmoud A.A. Mahmoud,d Wagnat W. Wardakhan,e Mervat S. Mohamed,a,f Ali Saber Abdelhameedg

\*aDepartment of Biochemistry, Faculty of Science, University of Tabuk, Kingdom of Saudi Arabia.

Tabuk 71491, P. O. Box 741.

bDepartment of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

cBiophysics Department, Faculty of Science, Cairo University, Giza, Egypt

dDepartment of Chemistry, Faculty of Science, University of Tabuk, Kingdom of Saudi Arabia, Tabuk 71491, P. O. Box 741.

eEgyptian Drug Authority (EDA) (NODCAR), Cairo, P.O. 29, Egypt

fDepartment of Chemistry, Faculty of Science, University of Tabuk, University of Tabuk, Kingdom of Saudi Arabia

gDepartment of Pharmaceutical Chemistry, College of pharmacy, King Saud University, Riyadh,11451, Kingdom of Saudi Arabia.

Twenty-two novel halogenated compoundswere tested for their binding affinity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)main protease (Mpro), in comparison to Nelfinavir. Three compounds resided in the active site pocket of the SARS-CoV-2 Mpro, superimposed over Nelfinavir, suggesting the same mode of interaction and potential antiviral activity.

